目錄:MedChemExpress LLC>>生化試劑>> Durvalumab | MCE
CAS | 1428935-60-7 | 純度 | 99.60% |
---|---|---|---|
供貨周期 | 現(xiàn)貨 | 規(guī)格 | 5 mg |
貨號 | HY-P9919 | 應用領(lǐng)域 | 醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥 |
MCE 的所有產(chǎn)品僅用作科學研究或藥證申報,我們不為任何個人用途提供產(chǎn)品和服務。
CAS No. : 1428935-60-7
產(chǎn)品活性:Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.
研究領(lǐng)域:Immunology/Inflammation
作用靶點:PD-1/PD-L1
In Vivo: Durvalumab inhibits tumor growth in mouse xenograft models of human melanoma (A375) and pancreatic (HPAC) tumour cell lines, via a T-cell-mediated mechanism. Durvalumab (5-0.01 mg/kg for NOD/SCID mice with HPAC tumor; 5-0.1 mg/kg for NOD/SCID mice with A375 tumor; administration i.p.; twice per week; for 3 weeks) significantly inhibits the tumor growth of both HPAC and A375 xenografts compared with an isotype-matched control antibody. Tumor growth inhibition of the HPAC cells reaches 74%, whereas inhibition of the A375 cells reaches 77%. When administered in the absence of T cells, Durvalumab has no effect on the growth of the A375 tumor xenograft.
相關(guān)產(chǎn)品:Rulonilimab | PD-1/PD-L1-IN-19 | [D-Leu-4]-OB3 | NSC622608 | Sulindac | BMS-1166 | PD-1/PD-L1-IN-18 | Pacmilimab | Anti-Mouse PD-L1 Antibody | Vudalimab | PD-1/PD-L1-IN-24 | Cetrelimab | Human PD-L1 inhibitor III | PD-1/PD-L1-IN-20 | PD-1-IN-20 | PD-1/PD-L1-IN 5 | Sintilimab | PD-1/PD-L1-IN-9 hydrochloride | Nivolumab | PD-1/PD-L1-IN-16 | WL12 | PD-1/PD-L1-IN 6 | Acasunlimab | PD-1/PD-L1-IN-14 | PD1-PDL1-IN 1 | Sugemalimab | MAX-10181 | PD-1/PD-L1-IN-23 | D18
熱門產(chǎn)品線:重組蛋白 | 化合物庫 | 天然產(chǎn)物 | 熒光染料 | PROTAC | 同位素標記物 | 寡核苷酸 | 抗體 | 點擊化學
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種全球僅有化合物庫,我們致力于為全球科研客戶提供前沿的高品質(zhì)小分子活性化合物;
• 50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領(lǐng);
• 產(chǎn)品種類涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產(chǎn)品,廣泛應用于新藥研發(fā)、生命科學等科研項目;
• 提供虛擬篩選,離子通道篩選,代謝組學分析檢測分析,藥物篩選等專業(yè)技術(shù)服務;
• 設(shè)有專業(yè)的實驗中心和嚴格的質(zhì)控、驗證體系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質(zhì)檢報告,確保產(chǎn)品的高純度、高品質(zhì);
• 產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證;
• Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果;
• 專業(yè)團隊跟蹤最新的制藥及生命科學研究進展,為您提供全球新的活性化合物;
• 與世界各大制藥公司及著名科研機構(gòu)建立了長期的合作。